Molecular targeting to treat gastric cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 38

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Oct 14, 2014; 20(38): 13741-13755
Published online Oct 14, 2014. doi: 10.3748/wjg.v20.i38.13741

Table 1 Clinical trial of trastuzumab

Patients	Phase	Treatment	n	OS (m)	PFS (m)	RR
Advanced HER-positive gastric cancer as first line (TOGA)	III	5-FU + cisplatin or capecitabine + cisplatin	290	11.1	5.5	34.5%
Advanced HER-positive gastric cancer as first line (TOGA)	III	5-FU + cisplatin + trastuzumab or capecitabine + cisplatin + trastuzumab	294	13.8	6.7	47.3%

OS: Overall survival; PFS: Progression-free-survival; RR: Response rate; 5-FU: 5-fluorouracil.

Citation: Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755
URL: https://www.wjgnet.com/1007-9327/full/v20/i38/13741.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i38.13741

Aoyagi K, Kouhuji K, Kizaki J, Isobe T, Hashimoto K, Shirouzu K. Molecular targeting to treat gastric cancer. World J Gastroenterol 2014; 20(38): 13741-13755 [PMID: 25320512 DOI: 10.3748/wjg.v20.i38.13741]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.